Evidence map›Paper›PMID 36815038›Full record

ArticleActa pharmaceutica Sinica. B2023

Melatonin alleviates alcoholic liver disease

Zhaodi Che, Yali Song, Chengfang Xu, Wei Li, Zhiyong Dong, Cunchuan Wang, Yixing Ren, Kwok-Fai So, George L Tipoe, Fei Wang and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Liver diseases: epidemiology, causes, trends and predictions.Signal transduction and targeted therapy · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. The Protective Effect ofMolecules (Basel, Switzerland) · 2023
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Zhaodi CheClinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Yali SongClinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Chengfang XuDepartment of Obstetrics, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China.
Wei LiFaculty of Pharmaceutical Sciences, Toho University, Chiba 2748510, Japan.
Zhiyong DongClinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Cunchuan WangClinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Yixing RenDepartment of General Surgery, and Institute of Hepato-Biliary-Pancreas and Intestinal Disease, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China.
Kwok-Fai SoGMH Institute of CNS Regeneration, Guangdong Medical Key Laboratory of Brain Function and Diseases, Jinan University, Guangzhou 510632, China.
George L TipoeSchool of Biomedical Sciences, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, China.
Fei WangDivision of Gastroenterology, Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China.
Jia XiaoClinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
First Affiliated Hospital of Jinan University · CNChinese University of Hong Kong · HKSun Yat-sen University · CNAffiliated Hospital of North Sichuan Medical College · CNJinan University · CNToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic alcohol consumption causes liver steatosis, cell death, and inflammation. Melatonin (MLT) is reported to alleviate alcoholic liver disease (ALD)-induced injury. However, its direct regulating targets in hepatocytes are not fully understood. In the current study, a cell-based screening model and a chronic ethanol-fed mice ALD model were used to test the protective mechanisms of MLT. MLT ameliorated ethanol-induced hepatocyte injury in both cell and animal models (optimal doses of 10 μmol/L and 5 mg/kg, respectively), including lowered liver steatosis, cell death, and inflammation. RNA-seq analysis and loss-of-function studies in AML-12 cells revealed that telomerase reverse transcriptase (TERT) was a key downstream effector of MLT. Biophysical assay found that epidermal growth factor receptor (EGFR) on the hepatocyte surface was a direct binding and regulating target of MLT. Liver specific knock-down of

Indexed as

Alcoholic liver diseaseBinding receptorBiophysicsBRG1EGFRMelatoninSafetyTERT

Identifiers

PMID36815038
PMCPMC9939303
OpenAlexW4283719217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.